Journey Medical Earnings Call Transcripts
Fiscal Year 2025
-
EMROSI's launch drove 11% revenue growth and improved margins in 2025, with strong prescription uptake and refill rates. Adjusted EBITDA turned positive, and expanding payer coverage is expected to further boost profitability and sales in 2026.
-
Q3 2025 saw 21% revenue growth, led by Emrosi's strong launch and rapid prescriber adoption. Gross margin improved sequentially, adjusted EBITDA turned positive, and the company expects sustainable EBITDA positivity in Q4 as payer coverage for Emrosi expands.
-
A dermatology-focused pharmaceutical firm is experiencing rapid growth following the launch of Emrosi, a new oral therapy for rosacea that has shown superior efficacy and safety compared to the market leader. Prescription growth, payer access, and out-licensing deals are driving the company toward profitability in 2025.
-
Q2 2025 net revenue rose to $15M, driven by EMROSI’s strong launch and rapid prescription growth, offsetting Accutane declines. Gross margin improved to 67%, and cash remained stable at $20.3M. Management expects continued EMROSI momentum and margin gains.
-
Q1 2025 saw a successful EMROSI launch, contributing $2M to $13.1M in net revenue, with gross margin up to 64% and net loss narrowing to $4.1M. Early adoption is strong, payer coverage is expanding, and legacy brands are stabilizing amid competition.
-
Emrosi, a newly FDA-approved oral minocycline for rosacea, demonstrated superior efficacy and safety over Oracea in phase III trials. The company is set for an April launch, targeting rapid adoption through a strong sales force, broad payer coverage, and robust marketing, with financials and supply chain well-prepared.
Fiscal Year 2024
-
Met all 2024 guidance, with $56M revenue and positive adjusted EBITDA. Emrosi, a new oral rosacea drug, received FDA approval and is launching with strong clinical data and early payer coverage. 2025 guidance will follow initial launch results.
-
FDA approved Emrosi, a novel oral minocycline for rosacea, with head-to-head superiority over Oracea and no special post-marketing requirements. Launch is planned for early 2025, with broad insurance coverage and profitability expected in the first year.
-
Q2 2024 net product revenue reached $14.9 million, with core dermatology brands driving growth and positive non-GAAP Adjusted EBITDA for the fourth consecutive quarter. The company remains on track to meet 2024 guidance and is preparing for the anticipated DFD-29 launch, supported by strong clinical data and market interest.